Recruiting

CAR T-Cell Therapy

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05237986

Conditions

Lymphoma

Leukemia

Eligibility Criteria

Sex: All

Age: 5+

Healthy Volunteers: Accepted

Study Details

Brief summary:

Background:

CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically interested in learning if and how this treatment may affect the brain or your thinking skills.

Objective:

To learn if CAR T-cell therapy can affect how children and adults think, process, and remember things.

Eligibility:

People aged 5-35 who have blood cancer that has not responded to treatment, or the blood cancer has come back after treatment, and who will receive CAR T-cell therapy. Caregivers are also needed. All participants must be able to speak and read in English or Spanish.

Design:

Participants will be screened with a medical history.

Information from participants medical records will be collected.

Participants will take tests at home or at NIH to see how well they think, read, learn, remember, reason, and pay attention. The tests will be both computerized and paper/pencil. They will take less than 1 hour to complete.

Participants and a parent/adult observer will complete a 5-minute Background Information Form and a checklist of nervous system symptoms.

If participants are 5 years or older, they will participate in activities to test their ability to do different thinking tasks, like answer questions, complete puzzle patterns, and remember things.

Participants and their caregivers will complete questions to see if they are having specific symptoms related to receiving CAR T-cells. The questions will assess their well-being and needs. The questions will take less than 1 hour to complete.

Some tests and questions will be repeated at different time points in the study.

Participation will last for up to 3 years.

Conditions

Lymphoma

Leukemia

Study ID

NCT05237986

Start date

Jun 23, 2025

Status verified date

Aug 11, 2026

Completion date

Dec 1, 2028

Anticipated

Primary completion date

Sep 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 5+

Healthy Volunteers: Accepted

  • INCLUSION CRITERIA:
  • Participants with disease

  • Participants are diagnosed with relapsed/refractory leukemias or lymphomas, and are scheduled to receive CAR T-cell treatment in one of the enrolling sites
  • For participants enrolled on a CAR T-cell treatment protocol, data sharing for the purposes of this study must be allowed.
  • Age >= 5 and <=35 years old
  • Participant must have an eligible caregiver (informant) who is willing to complete assessments about the participant of this study
  • Participants (<18 years, or >=18 years if needed) must have an eligible caregiver to assist with setting up an appropriate test environment for the remote evaluations
  • Participant must be able to speak and understand English or Spanish
  • Participants must have access to a computer or tablet with a camera and an internet connection
  • Participant or parent/guardian must be able to understand and willing to sign a written consent document
  • Caregivers (informants)

  • Participants must be able to speak and read in English or Spanish
  • Participants who are caregivers for participants with disease addressed above
  • Age >= 18 years old
  • Participants must have access to a computer or tablet
  • Participants (of children <18 years, or >18 years if needed) must be willing to help set up an appropriate test environment for the remote evaluations
  • Participant is able to understand and willing to sign a written consent document

EXCLUSION CRITERIA:

-Participants with disease who have a pre-existing global intellectual disability (e.g., Down Syndrome)

Study Design

Enrollment

60 participants

Anticipated

Interventions and Outcome Measures

Arms

Cohort 1

Participants with relapsed/refractory leukemias or lymphomas, scheduled to receive CAR T-cell therapy.

Cohort 2

Caregivers (informants)

Primary outcome measure

  • To evaluate changes in working memory in children and young adults with relapsed/refractory leukemia or lymphoma at 12 months post CAR T-cell therapy [ Time Frame: 12 months post CAR T-cell therapy ]

Central Contacts and Locations

Central contacts

NCI Ped LeukemiaLymph Cell Tx Tm

(240) 760-6970ncilltct@mail.nih.gov

Locations

Children s Hospital of Los Angeles

Recruiting

Los Angeles, California, United States, 90027

Contacts

Ashley Whitaker, Ph.D., ABPP-CN

(323) 361-2744awhitaker@chla.usc.edu

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

Contacts

For more information at the NIH Clinical Center contact National Cancer Institute Referral Office

888-624-1937

Seattle Children s Hospital

Recruiting

Seattle, Washington, United States, 98105

Contacts

More Information

Sponsor

National Cancer Institute (NCI)

Last update posted

Aug 31, 2026

Last verified

Aug 11, 2026

Keywords

  • Cogstate
  • Memory
  • Leukemia
  • Lymphoma
  • Natural History

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-08-31.